170 related articles for article (PubMed ID: 19876942)
1. Binding of nitrogen-containing bisphosphonates (N-BPs) to the Trypanosoma cruzi farnesyl diphosphate synthase homodimer.
Huang CH; Gabelli SB; Oldfield E; Amzel LM
Proteins; 2010 Mar; 78(4):888-99. PubMed ID: 19876942
[TBL] [Abstract][Full Text] [Related]
2. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
Gabelli SB; McLellan JS; Montalvetti A; Oldfield E; Docampo R; Amzel LM
Proteins; 2006 Jan; 62(1):80-8. PubMed ID: 16288456
[TBL] [Abstract][Full Text] [Related]
3. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
[TBL] [Abstract][Full Text] [Related]
4. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates.
Aripirala S; Gonzalez-Pacanowska D; Oldfield E; Kaiser M; Amzel LM; Gabelli SB
Acta Crystallogr D Biol Crystallogr; 2014 Mar; 70(Pt 3):802-10. PubMed ID: 24598749
[TBL] [Abstract][Full Text] [Related]
5. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, calorimetry, and crystallographic analysis of 2-alkylaminoethyl-1,1-bisphosphonates as inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.
Aripirala S; Szajnman SH; Jakoncic J; Rodriguez JB; Docampo R; Gabelli SB; Amzel LM
J Med Chem; 2012 Jul; 55(14):6445-54. PubMed ID: 22715997
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants.
Tsoumpra MK; Muniz JR; Barnett BL; Kwaasi AA; Pilka ES; Kavanagh KL; Evdokimov A; Walter RL; Von Delft F; Ebetino FH; Oppermann U; Russell RGG; Dunford JE
Bone; 2015 Dec; 81():478-486. PubMed ID: 26318908
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
Montalvetti A; Bailey BN; Martin MB; Severin GW; Oldfield E; Docampo R
J Biol Chem; 2001 Sep; 276(36):33930-7. PubMed ID: 11435429
[TBL] [Abstract][Full Text] [Related]
9. Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site.
Liu YL; Lindert S; Zhu W; Wang K; McCammon JA; Oldfield E
Proc Natl Acad Sci U S A; 2014 Jun; 111(25):E2530-9. PubMed ID: 24927548
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the N-BP Binding at FPPS by Combined Computational Approaches.
Stefanucci A; Marrone A; Agamennone M
Med Chem; 2015; 11(5):417-31. PubMed ID: 25541745
[TBL] [Abstract][Full Text] [Related]
11. New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase.
Ferrer-Casal M; Li C; Galizzi M; Stortz CA; Szajnman SH; Docampo R; Moreno SN; Rodriguez JB
Bioorg Med Chem; 2014 Jan; 22(1):398-405. PubMed ID: 24300918
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase.
Rosso VS; Szajnman SH; Malayil L; Galizzi M; Moreno SN; Docampo R; Rodriguez JB
Bioorg Med Chem; 2011 Apr; 19(7):2211-7. PubMed ID: 21419634
[TBL] [Abstract][Full Text] [Related]
13. 2-alkylaminoethyl-1,1-bisphosphonic acids are potent inhibitors of the enzymatic activity of Trypanosoma cruzi squalene synthase.
Rodrígues-Poveda CA; González-Pacanowska D; Szajnman SH; Rodríguez JB
Antimicrob Agents Chemother; 2012 Aug; 56(8):4483-6. PubMed ID: 22585217
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase.
Park J; Rodionov D; De Schutter JW; Lin YS; Tsantrizos YS; Berghuis AM
PLoS One; 2017; 12(10):e0186447. PubMed ID: 29036218
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.
Demoro B; Caruso F; Rossi M; Benítez D; González M; Cerecetto H; Galizzi M; Malayil L; Docampo R; Faccio R; Mombrú AW; Gambino D; Otero L
Dalton Trans; 2012 Jun; 41(21):6468-76. PubMed ID: 22344249
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of chlorinated substrate analogues for farnesyl diphosphate synthase.
Heaps NA; Poulter CD
J Org Chem; 2011 Mar; 76(6):1838-43. PubMed ID: 21344952
[TBL] [Abstract][Full Text] [Related]
17. Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase.
Ohno K; Mori K; Orita M; Takeuchi M
Curr Med Chem; 2011; 18(2):220-33. PubMed ID: 21110804
[TBL] [Abstract][Full Text] [Related]
18. New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.
Fernández D; Ramis R; Ortega-Castro J; Casasnovas R; Vilanova B; Frau J
J Comput Aided Mol Des; 2017 Jul; 31(7):675-688. PubMed ID: 28631130
[TBL] [Abstract][Full Text] [Related]
19. Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.
Yin F; Cao R; Goddard A; Zhang Y; Oldfield E
J Am Chem Soc; 2006 Mar; 128(11):3524-5. PubMed ID: 16536518
[TBL] [Abstract][Full Text] [Related]
20. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
